The first-in-human SCS trial saw all three SMA patients able to increase their walking distance within six minutes to 20 meters.

Alys Pharmaceuticals has received clearance from the US FDA and Health Canada for a Phase IIa trial of ALY-101 for alopaecia ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...